Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
The present and future of measurable residual disease testing in acute myeloid leukemia | Haematologica
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients | Haematologica
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party - ScienceDirect
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML) | Leukemia
Relevance of NGS-based minimal residual disease (MRD) in AML
Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
MRD assessment in different therapeutic stadia of AML. | Download Scientific Diagram
a Minimal residual disease (MRD) in acute myeloid leukemia (AML) using... | Download Scientific Diagram
Clinical implications of measurable residual disease in AML: Review of current evidence - ScienceDirect
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML - ScienceDirect
Frontiers | MRD Tailored Therapy in AML: What We Have Learned So Far
NGS rEvolution - Minimal Residual Disease Detection
Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia | IntechOpen
What Is Minimal Residual Disease (MRD) in Leukemia? | MyLeukemiaTeam
How Is Minimal Residual Disease (MRD) Monitored in Leukemia? | MyLeukemiaTeam
What Is the Measure of Minimal Residual Disease in AML - The ASCO Post
MRD in AML: The Role of New Techniques | Semantic Scholar
Biomarkers Consortium – Measurable residual disease in acute myeloid leukemia (MRD in AML) | FNIH
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia | Leukemia
MRD Tailored Therapy in AML: What We Have Learned So Far. - Abstract - Europe PMC
